vs
Side-by-side financial comparison of Allstate (ALL) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Allstate is the larger business by last-quarter revenue ($922.0M vs $699.9M, roughly 1.3× QuidelOrtho Corp). Allstate runs the higher net margin — 266.6% vs -104.7%, a 371.3% gap on every dollar of revenue. On growth, Allstate posted the faster year-over-year revenue change (7.2% vs -3.7%). Over the past eight quarters, QuidelOrtho Corp's revenue compounded faster (-2.9% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
ALL vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $699.9M |
| Net Profit | $2.5B | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | -1400.3% | -100.7% |
| Net Margin | 266.6% | -104.7% |
| Revenue YoY | 7.2% | -3.7% |
| Net Profit YoY | — | -3583.4% |
| EPS (diluted) | $9.25 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | — | ||
| Q4 25 | $17.3B | — | ||
| Q3 25 | $17.3B | $699.9M | ||
| Q2 25 | $16.6B | $613.9M | ||
| Q1 25 | $16.5B | $692.8M | ||
| Q4 24 | $16.5B | $707.8M | ||
| Q3 24 | $16.6B | $727.1M | ||
| Q2 24 | $15.7B | $637.0M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $3.8B | — | ||
| Q3 25 | $3.7B | $-733.0M | ||
| Q2 25 | $2.1B | $-255.4M | ||
| Q1 25 | $595.0M | $-12.7M | ||
| Q4 24 | $1.9B | $-178.4M | ||
| Q3 24 | $1.2B | $-19.9M | ||
| Q2 24 | $331.0M | $-147.7M |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% |
| Q1 26 | 266.6% | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 21.7% | -104.7% | ||
| Q2 25 | 12.7% | -41.6% | ||
| Q1 25 | 3.6% | -1.8% | ||
| Q4 24 | 11.7% | -25.2% | ||
| Q3 24 | 7.2% | -2.7% | ||
| Q2 24 | 2.1% | -23.2% |
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | — | ||
| Q3 25 | $13.95 | $-10.78 | ||
| Q2 25 | $7.76 | $-3.77 | ||
| Q1 25 | $2.11 | $-0.19 | ||
| Q4 24 | $7.07 | $-2.54 | ||
| Q3 24 | $4.33 | $-0.30 | ||
| Q2 24 | $1.13 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $98.1M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $31.6B | $2.0B |
| Total Assets | $124.0B | $5.7B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | — | ||
| Q3 25 | $8.7B | $98.1M | ||
| Q2 25 | $9.6B | $151.7M | ||
| Q1 25 | $6.5B | $127.1M | ||
| Q4 24 | $4.5B | $98.3M | ||
| Q3 24 | $7.0B | $143.7M | ||
| Q2 24 | $5.3B | $107.0M |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $8.1B | $2.5B | ||
| Q2 25 | $8.1B | $2.1B | ||
| Q1 25 | $8.1B | $2.1B | ||
| Q4 24 | $8.1B | $2.1B | ||
| Q3 24 | $8.1B | $2.2B | ||
| Q2 24 | $8.1B | $2.2B |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | — | ||
| Q3 25 | $27.5B | $2.0B | ||
| Q2 25 | $24.0B | $2.8B | ||
| Q1 25 | $22.1B | $3.0B | ||
| Q4 24 | $21.4B | $3.0B | ||
| Q3 24 | $20.9B | $3.2B | ||
| Q2 24 | $18.6B | $3.2B |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | — | ||
| Q3 25 | $120.4B | $5.7B | ||
| Q2 25 | $115.9B | $6.4B | ||
| Q1 25 | $115.2B | $6.5B | ||
| Q4 24 | $111.6B | $6.4B | ||
| Q3 24 | $113.7B | $6.8B | ||
| Q2 24 | $108.4B | $6.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.29× | 1.23× | ||
| Q2 25 | 0.34× | 0.74× | ||
| Q1 25 | 0.37× | 0.70× | ||
| Q4 24 | 0.38× | 0.72× | ||
| Q3 24 | 0.39× | 0.68× | ||
| Q2 24 | 0.43× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.3B | $-45.5M | ||
| Q2 25 | $1.9B | $-46.8M | ||
| Q1 25 | $2.0B | $65.6M | ||
| Q4 24 | $1.7B | $63.7M | ||
| Q3 24 | $3.2B | $117.9M | ||
| Q2 24 | $2.4B | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $3.2B | $-94.7M | ||
| Q2 25 | $1.9B | $-84.3M | ||
| Q1 25 | $1.9B | $9.4M | ||
| Q4 24 | $1.7B | $16.5M | ||
| Q3 24 | $3.1B | $71.4M | ||
| Q2 24 | $2.3B | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | — | ||
| Q3 25 | 18.8% | -13.5% | ||
| Q2 25 | 11.3% | -13.7% | ||
| Q1 25 | 11.4% | 1.4% | ||
| Q4 24 | 10.0% | 2.3% | ||
| Q3 24 | 18.9% | 9.8% | ||
| Q2 24 | 14.7% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.3% | 7.0% | ||
| Q2 25 | 0.0% | 6.1% | ||
| Q1 25 | 0.6% | 8.1% | ||
| Q4 24 | 0.3% | 6.7% | ||
| Q3 24 | 0.4% | 6.4% | ||
| Q2 24 | 0.4% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.88× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 3.30× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 2.69× | — | ||
| Q2 24 | 7.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALL
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
